1. In Vivo
  2. >>Business Strategy

Esperion, Again: Pfizer's First Spin-Out's Familiar Look

This examination of Pfizer's first foray into spin-outs is a sidebar to "Can Out-Partnering Power Pfizer Over the "Second Cliff?"" Pfizer's Esperion spin-out hopes to pick up where it left off five years ago when Pfizer bought its first incarnation: developing HDL-raising therapies for CV disease.

The Pfizer Inc. building in Ann Arbor, Michigan, which housed the former Esperion Therapeutics closed its doors more than a year ago as part of a broad corporate restructuring in the wake of Pfizer’s well-publicized torcetrapib disappointment in late 2006. (See "Best Laid Plans: Pfizer’s Torcetrapib Tanks," IN VIVO, December 2006 Also see "Best Laid Plans: Pfizer's Torcetrapib Tanks" - In Vivo, 1 December, 2006..) But in fact Pfizer’s other efforts in raising HDL were already withering —despite the boost from the late-2003 acquisition of Esperion for $1.3 billion, in large part for that company’s good-cholesterol mimetic Apo A-1 Milano (a.k.a. ETC-216). [See Deal] (See "A Recipe for Acquisition: the Esperion Strategy," IN VIVO, January 2004 Also see "A Recipe for Acquisition: the Esperion Strategy" - In Vivo, 1 January, 2004..) Essentially everything that came into Pfizer via Esperion was either shelved from the outset or quietly discontinued before torcetrapib’s demise "for scientific and technical reasons," according to a spokesperson.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By Mike King

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

Aurion Biotech’s Ophthalmic Cell Therapy For The Masses

 
• By David Wild

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

Neurodegenerative Disease Investment: Shifting Paradigms Beyond Amyloid And Tau

 
• By David Wild

Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.

Licensing For Innovation: A Decade Of Pharma Product Deals

 
• By Edwin Elmhirst

Licensing deals have been growing in popularity over outright acquisitions in the pharmaceutical industry over the past decade. Licensing deals have doubled in number from 2015 to 2024, while M&A activity has decreased post-COVID. We consider the advantages of licensing deals and review notable licensing deals from the past 10 years with the potential to deliver high value relative to their initial investment.

More from In Vivo

Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal

 
• By Brian Yang

Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.

Rising Leaders 2025: Amir Hefni Puts Optimism Into Action At Resolution Therapeutics

 
• By Jo Shorthouse

In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.

In Vivo’s 2025 Rising Leaders

 
• By Jo Shorthouse

The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.